2 citations
,
June 2024 in “Journal of the American Academy of Dermatology” This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.
April 2024 in “Pharmacoepidemiology and drug safety (Print)” This study found that using at least one ICD-10 code for alopecia in Medicaid claims data accurately identified alopecia in women of childbearing age, with positive predictive values between 95.3% and 100% across various algorithms tested.
29 citations
,
December 2022 in “Dermatology and Therapy” This study reported that patients with alopecia areata experienced significant increases in work productivity loss and activity impairment due to worsening emotional symptoms, highlighting a need for better treatments.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.
November 2025 in “SKIN The Journal of Cutaneous Medicine” In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.
